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I.

Abstract:
Observing and designing the in vivo distribution and localization of therapeutic
nanoparticles is an essential aspect of developing and understanding novel nanoparticlebased medical treatments. This study investigates novel PEGylated Iodine-based
nanoparticles (INPs), an alternate composition to the more widely researched gold
nanoparticles (AuNPs), which may help avoid adverse effects associated with AuNPs, such
as potential toxicity and skin discoloration, when used in similar applications. Determining
the localization of the novel INPs within murine brains containing human glioma U-1242MG
cells is critical in assisting the development of radiation dose enhancement therapy for this
aggressive cancer. Radiation dose enhancement utilizes the increased radiation absorption of
the INPs and subsequent increased electron and photon scattering to increase the therapeutic
effect and possibly help reduce the radiation dose administered. This study serves to
qualitatively and semi-quantitatively determine the distribution of the novel INPs within the
murine brain, the tumor region, and at the cellular level within the tumor. This is
accomplished through immunofluorescence staining and light and confocal microscopy,
probing for CD31 (PECAM1), an endothelial cell marker, poly(ethylene glycol) (PEG), a
nanoparticle marker, DAPI, a nucleus marker, and tdTomato, a fluorescent protein expressed
by the implanted U-1242MG cells. The imaging at 10X and 63X magnification yielded
evidence that the PEGylated INPs are distributed in and around the tumor to a much greater
extent than elsewhere in the brain and there is some propensity for the INPs to localize in the
vasculature far from the tumor region as well as within the tumor region. At the cellular level
the INPs are not regularly taken up by cells and introduced into the cytoplasm within 24
hours of the last injection. Therefore, this study is relevant to radiation therapy in that it
further characterizes the behavior of INPs in glioma containing murine brains, and from the
data on where these particles exist, researchers can eventually develop a correlation of
therapy results with INP localization at the cellular level to better develop patient treatments.
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II.

Introduction:
Radiation Dose Enhancement:
Radiation therapy is a fundamental element in the treatment of brain tumors and is
frequently used in conjunction with surgical excision and chemotherapy. In regards to
glioblastoma multiforme (GBM), radiotherapy is considered the standard of care when
combined with the chemotherapeutic temozolomide [1]. In fact, radiation therapy has the
potential to be useful as a curative treatment method in 25 % of all new cancer cases, and as
palliative care in an additional 25 % of new diagnoses [2]. Nonetheless, though radiation
therapy can kill malignant cells, and slow or halt the growth of tumors, by inducing DNA
damage which interrupts the cellular division process ultimately leading to apoptosis or
latency [3], it can also damage or kill healthy brain tissue and ultimately lead to radiation
necrosis [2, 4, 5]. Radiation necrosis, which is essentially healthy brain tissue death
following radiation therapy, often appears 6 months to 2 years after treatment due to the
delayed cellular response to DNA damage acquired during radiation therapy in healthy
tissues [4]. In particular, the endothelial cells of smaller blood vessels are most often affected
and their death recruits lymphocytes and macrophages, which in turn trigger a cascade of
cytokine activity and an inflammatory immune response. Ultimately, the inflammation
induces new, though irregular vascular growth very prone to thrombosis and hemorrhage,
leading to ischemic injury in healthy brain tissues [4]. Additionally, there are significant side
effects associated with radiation necrosis including headache, drowsiness, memory loss,
personality change, seizures, and even eventual death, while there are few well-studied
treatment options for the condition [4].
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One possible approach under development to mitigate the damage to healthy tissue is the
use of heavy-atom-based nanoparticles to amplify radiation doses within tumors while
delivering a less toxic dose to normal tissues [6, 7, 8, 9]. If heavy-atom based nanoparticles
are loaded into tumors by any means, radiation dose enhancement is possible due to the
increased absorbance of X-rays and subsequent increase in scattered electrons, ions, radicals,
and other reactive chemical species in tissues due to the higher concentrations of heavy
atoms present in the tumor [6]. Therefore, by exploiting the enhanced permeability and
retention (EPR) effect of nanoparticles within tumors due to the malformed and leaky
vasculature present in some tumors, nanoparticles can be distributed throughout a tumor by
minimally invasive intravenous injection [10]. Thus, as researchers have shown dose
enhancement with gold nanoparticles or iodine contrast media [6, 7, 8, 9], our lab seeks to
demonstrate radiation dose enhancement with novel, PEGylated iodine-based nanoparticles.
The INPs have the potential to avoid the renal toxicity of iodinated molecules [11] and the
various disadvantages of gold nanoparticles including discoloration of the skin and the
possibility of toxicity of gold nanoparticles presented in some studies but not in others
[reviewed in 12].
a. PEGylation of Nanoparticles:
Due to the small size and high surface area to volume ratio of nanoparticles, there is a
substantial fraction of the total number of atoms of the nanoparticles at the surface, with
uncoordinated bonds. This results in a very high surface energy for small particles and the
subsequent aggregation and adsorption of other nanoparticles and molecules in order to
reduce the fraction of atoms with “dangling bonds”, and therefore reduce the overall surface
energy. In order to mitigate this effect and retain nanoparticle size, ligands are often attached
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to nanoparticles to resist protein adsorption and particle aggregation in an in vivo
environment. The industry standard ligand that has emerged for this function has been
poly(ethylene glycol) (PEG), a polyether which has been shown to be hydrophilic and
bioinert [14, 16]. These properties, as well as the polymer’s size allow particles with attached
PEG ligands to increase their solubility and hydrodynamic size by increasing the amount of
coordination sites for the aqueous solvation layer, allowing the avoidance of renal clearance,
and a subsequent increase in circulation time [15]. Likewise, the bioinert behavior of PEG
allows it to be used as a “stealth” agent on nanoparticles and other molecules, allowing
PEGylated particles to avoid the immune system response as well as non-specific cellular
uptake mostly by the reticuloendothelial system of the liver (RES), further increasing the
circulation time [14, 15, 17]. This “stealth” effect is possible because the hydrophilic
polymers resist opsonin binding, therefore resulting in fewer nanoparticles marked for
endocytosis [18]. With enhanced circulation times, more drugs or nanoparticles are capable
of being dispersed or deposited in the desired location, selected for by additional specific
surface protein binding ligands or in the case of some tumors, the already existing, leaky
vasculature, which enables blood borne molecules to enter the tumor interstitium [19, 20].
The novel iodine-based nanoparticles used in this study have been PEGylated to exploit
the same phenomena mentioned above. Further, the PEG ligands are the molecules that are
probed for with immunofluorescence imaging to determine the localization of the
nanoparticles.
b. Human Glioma U-1242MG:
The model cell strain used in this experiment was U-1242MG, a human glioma. As a
glioma, or a cancer arising from the glial cells of the brain, these cells are adapted to living in
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brain tissue and thus are capable of rapid growth and invasion of healthy tissue. These
tumors, referred to as glioblastomas when displaying highly invasive and proliferative
behavior, are noted for having hyperplastic blood supplies as well. It is worth noting that due
to the ability and tendency of U-1242MG cells to grow amongst healthy brain tissue,
symptoms are not generally observed until the tumor is already quite large [21].
In this study, the implanted U-1242MG cells were transduced by Northwestern
University to express the protein firefly luciferase as well as the fluorescent protein
tdTomato. Hence the tumor could be monitored while growing with bioluminescence and
viewed histologically by fluorescent microscopy.
c. Previous Research and Results
There have been several studies concerning the localization of PEGylated nanoparticles,
including gold-based and polymer-based nanoparticles [22, 23]. The localization on the
intercellular and intracellular level is ultimately dependent on the specific uptake proteins
ligated to the nanoparticles as well as the final diameter of the nanoparticles [22]. In
particular, the findings reported concerning PEGylated gold nanoparticles (AuNPs) stated
that 2.4 nm AuNPs localized in the nucleus once internalized, 5.5 – 8.2 nm AuNPs localized
in the cytoplasm, and nanoparticles greater than 16 nm in diameter were not permitted into
the cells and localized at the cellular periphery [22]. This study aims to characterize and
compare the localization of the novel INPs with the results in these findings since there are
similarities in the PEG nanoparticle surface, but differences in the core composition. Lastly,
the novel INPs do not have specific cellular uptake proteins attached and therefore will not
extensively use receptor-mediated endocytosis.
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III.

Materials & Methods:
a. Materials:
•

•

•

•

Implantation
• 8 week old, female, athymic nude mice; n = 3
• U-1242MG cells expressing tdTomato fluorescent protein
• 1-microliter syringe
• Drill
• Scalpel
• Surgical Glue
• Ketamine/Xylazine anaesthetic
• Alcohol swabs, Betadine, Gauze pads
Injection
• PEGylated Iodine-based nanoparticles (INP)
• 25 gauge syringe
• Tail vein mouse restrainer
Sectioning
• Cryomatrix
• Glass microscope slides
• Pink slide tape/Japanese tape
• Leica CM3050 S Research Cryostat
Staining
• Primary Antibodies
• Goat-anti-Mouse/Rat CD31 diluted 1:100 in 1% BSA
solution from R&D AF3628
• Rabbit-anti-PEG diluted 1:500 in 1% BSA solution from
Abcam ab51257
• Secondary Antibodies
• Donkey-anti-Rabbit conjugated with Alexa Fluor 488
diluted 1:400 in 1% BSA solution from Invitrogen a21206
• Donkey-anti-Goat conjugated with Alexa Fluor 647 diluted
1:200 in 1% BSA solution from Life Technologies a21447
• Solutions
• Washing solution (phosphate-buffered saline (PBS))
• Blocking Solution (1:10 dilution of PowerBlock in PBS)
• Antibody Diluent (1% Bovine Serum Albumin in PBS)
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Coverslip Mounting Solution (1:1000 Hoescht 33342 in
50% v/v Glycerol in PBS)
• Coplin Jars
• 1000 microliter, 100 microliter, 20 microliter, and 5 microliter
micropipettes
Imaging
• Fluorescence Light Microscope – Zeiss Axio Observer Z1
• Confocal Microscope – Zeiss LSM 880
• Zen Black/Zen Blue imaging software & Fiji image processing
software
•

•

b. Methods:
Implantation of the human glioma U-1242MG cells into the brains of three, 8 week
old, female, athymic, nude mice: Mice were sedated with an intraperitoneal injection of
the ketamine/xylazine drug cocktail of approximately 90 mg/kg and 5 mg/kg dosages
respectively. Upon complete sedation determined by the lack of a pedal or toe pinch
reflex, a dorsal incision was made on each mouse’s head to reveal the skull beneath.
Next, with the 450-micrometer micro-drill, a hole was made through each skull and dura
revealing the left hemisphere of the brain. A 27 gauge needle fitted with a 2.5 – 3 mm
plastic, depth limiting collar connected to a 1-microliter syringe previously loaded with
~100,000 U-1242MG cells was then introduced carefully into each opening. The cells
were then injected over the course of 1 minute and a total volume of 1 microliter. One
minute later the needle was then removed and the skin was sutured using surgical glue to
close the incisions.
Tumor Monitoring and INP Administration: The implanted tumors were then
monitored using the In Vitro Imaging System (IVIS) Spectrum machine for 2-3 weeks to
track tumor growth. After successful tumor growth indicated by a set signal threshold
from the tumor, the mice were then injected 4 times with INP at 1.75 g I/kg body weight
over 48 hours, with two injections 3 hours apart on two consecutive days. 24 hours
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following the final injection the mice were deeply anesthetized and subjected to perfusion
fixation.
Perfusion Fixation and Tissue Harvesting: Each mouse was anesthetized with the same
surgical dose of the ketamine/xylazine cocktail described previously and monitored using
the to pinch method for full anesthesia. Upon full anesthesia, each mouse was secured on
its back with its limbs spread away from its body. A transverse incision was made
through the skin of the abdomen followed by the muscle layer into the abdominal cavity
of the mouse, careful to avoid any internal organs. Next, curved, blunt scissors were used
to cut the ribs from the lateral incision toward the collarbone on each side. Tissue
connecting the heart to the sternum was carefully trimmed away allowing for the rib cage
to be held in place over the animal’s head using a hemostat. A 15 gauge blunt needle was
then introduced through the left ventricle into the ascending aorta and the right atrium
was cut to allow for blood to drain from the circulatory system. Immediately following
the laceration of the atrium, PBS was delivered through the needle for approximately 10
– 15 seconds followed by 10% formalin. This fluid was administered until the mouse was
fully stiff and no further blood drained from the atrium. The brains were then harvested
by resecting the skull and stored for 24 hours in a 10% formalin solution at 4° C. The
brains were transferred to a 30% sucrose solution overnight at 4° C. Finally, the brains
were cut laterally, mid-tumor and were submerged in Cryomatrix and frozen in dry ice
cooled isopentane.
Cryosectioning: Once the blocks were prepared, microscope slide sections were
prepared using the Leica CM3050 S Research Cryostat. A selected block was mounted
onto a chilled pedestal, and aligned with the blade of the machine to ensure consistent
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and level 7-micrometer sections with every cut. For each specimen sample, a section of
microscope slide tape was applied to the mounted block and firmly secured with the use
of a roller. The sample was then taken and quickly transferred to a chilled glass
microscope slide. This process was repeated for the desired number of sections from
various regions of the brains. The samples were then cross-linked to the slides with UV
light.
Immunofluorescence Staining: Enough sections were taken to provide a series of
controls for the staining protocol. This included sections stained with no antibodies, only
primary antibodies, only secondary antibodies, individual combinations of primary and
secondary, and all antibodies. Previous work in our lab has ruled out any non-exclusive
and undesired antibody-antibody interactions as well as non-specific antigen labeling
when using this specific set of antibodies. However, an isotype antibody control was not
performed followed by a secondary antibody to determine the presence of any
background signal. The same staining protocol was used for all slides and all antibody
combinations and is described below.
All slides were placed in Coplin jars and rehydrated in PBS for 10 minutes. The slides
were then removed and dried with Kimwipes, avoiding contact with any tissue on the
slide. Next, each section was blocked using 100 microliters of the blocking solution,
applied with a 100-microliter micropipette, ensuring full coverage of each individual
section, avoiding tissue contact with the pipette. After 30 minutes, the blocking solution
was removed by tilting each slide perpendicular to the work surface and tapping gently to
dislodge the liquid. The slides were then placed back in the Coplin jars and washed in
PBS for 5 minutes to remove any excess blocking solution. The slides were then
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removed, dried, and prepared for the primary antibody addition. First, the primary
antibody solution containing both primary antibodies was prepared in the proper dilution
ratio for each antibody. Each section was then stained according to its series designation
with approximately 80 microliters of its given antibody solution. To sections serving as
controls and receiving neither of the two primary antibodies, a 1% BSA solution was
applied. All slides were then incubated overnight at 4°C in a humidified environment.
Following the primary antibody incubation, the antibody solutions were removed and
the slides were placed in Coplin jars and washed in PBS 3 times for 5 minutes each and
then dried as described above. Similarly, one solution was prepared containing both
secondary antibodies in their proper dilution ratios. Each section was then stained
according to its series designation, again with approximately 80 microliters of staining
solution. To sections receiving neither of the two secondary antibodies, 1% BSA in PBS
was applied. The slides were then placed in a humidified environment and allowed to
incubate at room temperature for 60 minutes. The slides were the washed 3 times in PBS
for 5 minutes each wash and then dried and prepared for coverslip mounting.
The coverslip mounting media was prepared by adding 500 microliters of glycerol to
500 microliters of PBS in a 3 mL microcentrifuge tube. This solution was thoroughly
mixed using a test tube vortex mixer. One microliter of the Hoescht 33342 stain was then
added to the glycerol-PBS mixture and the solution was mixed using the vortex mixer
again. Finally, using a 20-microliter micropipette, about 6 to 8 microliters of the prepared
coverslip mounting media was applied to each section. A glass coverslip was then slowly
lowered onto each slide taking care to trap as few air bubbles as possible. Lastly, using
Kimwipes, any excess mounting media was removed by gently patting the edges of each
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slide, taking care to not smudge or smear any solution across either glass surface. The
prepared slides were then stored at -20°C in sealed container until they were imaged.
Fluorescence Imaging: All imaging was performed using either the Zeiss Axio Observer
Z1 fluorescence light microscope or the Zeiss LSM 880 confocal microscope and images
were processed using the Zen Blue software and the open-source software variant of
ImageJ called Fiji. Images were taken in several formats including 10X magnification
tile-scans and 20X magnification single frame images using the Zeiss Axio Observer Z1,
and 63X magnification single frame images and 63X magnification z-stacks using the
Zeiss LSM 880 confocal microscope.
IV. Results:
a. 10X Magnification Tile Scan:
In order to investigate the general localization of the novel INP, a tile-scan of the
entire brain section containing the tumor region in the left hemisphere with a tumor free
right hemisphere was taken on the Zeiss Axio Observer Z1. This tile-scan, conducted at
10X magnification, allowed moderate resolution over the entire surface with a white
arrow indicating the center of the main tumor mass. The images demonstrated a much
greater PEG signal in the hemisphere with implanted U-1242MG cells, as is evident in
Figure 1d. Additionally, an overall increase in CD31 signal was obtained in and around
the tumor region (Figure 1c).
In the region of interests marked in colored boxes in Figure 1b, the tile scan
image is utilized to determine if the localization of PEG occurs at sites exhibiting CD31
signals. In the first region of interest marked by the red box in Figure 1b, an area lying
along the midline of the brain far from the tumor, there is a strong correlation of PEG and
CD31 signal, with little PEG signal outside of the regions exhibiting CD31 signal. This is
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evident in Figure 2, and further in Figure 3, which shows the PEG stain more
completely mapping the small vessels in the brain than the CD31 stain. This might be
possible because more PEG molecules were trapped and exposed to the immunostaining
antibodies than CD31 molecules, which are present at the intercellular junction sites,
which may not all be exposed to the surface, or it is possible the antibody binding affinity
of PEG is greater than that of CD31, thus increasing the fluorescent signal possible.

a)

b)

Figure 1a & 1b: 10X Tile Scan of murine brain with tumor present as
well as INP. The image shows nuclei colored blue (a), U-1242MG cells
colored red (b), endothelial cell marker CD31 colored cyan (c), and PEG
colored green (d). The white arrow points to the center of the tumor.
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c)

d)

Figure 1c & 1d: 10X Tile Scan of murine brain with tumor present as well
as INP. The image shows nuclei colored blue (a), U-1242MG cells colored
red (b), endothelial cell marker CD31 colored cyan (c), and PEG colored
green (d). The white arrow points to the center of the tumor.
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Figure 2: Region of interest 1 (red box in Figure 1c) outside of the tumor showing
localization of PEG (right) in regions with CD31 endothelial marker staining (left). The
channels for the U-1242MG cells and the cell nuclei stains were omitted because there
was no tumor signal and cell nuclei were uniformly present at this magnification.

Figure 3: Region of interest 2 outside of the tumor (orange box) showing PEG (right)
and CD31 (left) co-localization. In fact, in this image, the anti-PEG staining seems to
map the vasculature of the section better than the CD31 staining, likely due to the much
higher concentration of PEG antigens and subsequent contrast of the PEG stain.
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In Figures 4 & 5 regions of interest within the tumor were explored using 10X
magnification to determine any correlation of PEG localization with CD31 expression within the
tumor region, as well as in relation to tdTomato expressing U-1242MG cells and non-expressing
native tissues. As is evident in Figure 4, there is a large signal indicating near uniform PEG
distribution throughout the tumor, among both cancerous and non-cancerous cells. Likewise, in
Figure 5 several large vessels are clearly present, formed within tumor cell clusters, and
exhibiting significant signal from both CD31 and PEG staining. Additionally, Figure 6 shows a
10X magnification image with CD31, PEG, nuclei, and U-1242MG cells individually and
overlaid. The result is a clear display of a high amount of CD31 antigens, a near uniform
distribution of cell nuclei, a heterogeneous distribution of U-1242MG cells, displaying the
invasive nature of this strain, and a near uniform distribution of PEG throughout this region.
Nonetheless, the localization of the PEG is not clear at 10X magnification at the cellular level.
In order to address the ambiguity of the localization of the PEG signals at 10X
magnification, a series of z-stack confocal microscopy images were taken on the Zeiss LSM 880
microscope at 63X magnification. Figure 7 displays 3 levels of the stack selected to display a
change in the PEG signal as the plane of focus proceeded into the center of a layer of cells.
Additionally, in Figure 7 a region of interest containing a strong signal for CD31 and PEG is
highlighted. From this series it appears that the PEG signal is strongest at the surface and exterior
of cells as well as in vessels and voids within the tissue. As this z-stack proceeded, the PEG
signal further decreased, appearing only along the edges before increasing much like the top
plane. A possible explanation for this behavior is the inability for the antibodies to effectively
penetrate and stain intracellular PEG, which would alternatively explain why the PEG was not
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seen localized in the cells, however as discussed later a membrane permeabilizer used in a
staining protocol may confirm or deny this theory.
Finally, a quantitative analysis of the colocalization of the different signals was
performed using the Pearson’s Correlation Coefficient (PCC). This scale disregards signal
intensity and simply compares signal presence at the same pixels in an image over different
channels. The scale is from -1 to 1, with -1 signifying perfect antilocalization, 0 signifying no
correlation, and 1 signifying perfect correlation. Using Figure 6, it was found within the tumor
there was a PCC of -0.01 between the tumor cells and the PEG signal, indicating no specificity,
and a PCC of 0.3 between the PEG and CD31 signals, indicating low to moderate colocalization
specificity. Additionally, the PEG and CD31 PCC values were calculated for Figures 2 through
5 to determine the colocalization propensity of PEG with CD31. PCC values outside the tumor in
the regions of interest were 0.47 and 0.63 for Figure 2 and 3 respectively, indicating moderate
colocalization. PCC values within the tumor in the regions of interest displayed in Figures 4 and
5 were 0.75 and 0.65 respectively indicating a strong correlation between the localization of
CD31 and PEG signals. At 63X using Figure 7 the PCC value between PEG and CD31 was
0.42, the PCC value between PEG and tdTomato was 0.05, and the PCC between PEG and
nuclei was -0.10. It should be noted that the slight background present in these images is
considered using the PCC metric, and the backgrounds of tdTomato was significant, bringing the
PCC between PEG and tdTomato closer to 0. The results are summarized in the bar graph at the
end of the results section.
Lastly, several calculations were done using Figure 1 to determine the fractional area
occupied by the tumor and the fraction of the PEG signal this area contained. Ultimately the
tumor occupied about 16.5 percent of the sectional area and contained approximately 40 percent
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of the PEG signal. This demonstrates the EPR effect and that PEG is loaded in the tumors more
than outside of the tumor region. However, it also shows that about 60 percent of the signal
related to PEG occurs outside the tumor region.

Figure 4: Region of interest 1
inside of the tumor (yellow box).
This region shows extensive PEG
accumulation within the tumor (top
right), moderate and near uniform
CD31 expression (top left), and
heterogeneous tdTomato
expression (right), demonstrating
the invasive nature of the U1242MG cells and their ability to
grow amongst healthy tissue.
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Figure 5: Region of interest 2
within the tumor (purple box of
1b). As in Figure 4, this image
supports extensive PEG
accumulation within the tumor (top
right) around both the native cells
and U-1242MG cells. Additionally,
the top left image shows significant
CD31 staining indicating large
blood vessels present. The PEG
stain in the top right demonstrates
localization in and around these
larger vessels.
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b.

10X Magnification Snaps:

Figure 6: 10X magnification
images of the tumor region
showing CD31 (top left), nuclei
(middle left), U-1242MG (middle
right), and PEG (top right).
Additionally, a composite image of
all 4 channels is shown bottom
right. These images show PEG in
both healthy and cancerous tissue
withing the tumor.
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c.

63X Magnification Images:

Figure 7: 63X z-stack images of the tumor
region showing images taken 6 layers apart. All
three show PEG (green), nuclei (blue), CD31
(magenta), and U-1242MG cells (red). In the
top left image there is a vessel with a large
signal as well as a high amount of PEG signal,
leading to the cyan color in the box.
Additionally, at there is evidently more PEG
staining on the surface of the section (left) than
in the mid-section images (top right and bottom
right) implying higher membrane affinity than
cytosolic affinity.
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Chart 1: Pearson's Correlation Coefficients

V.

Discussion:
The images presented in the results section contain qualitative information detailing the

extent of tumor growth, the endothelial vascularization of the brain’s tissues, including
within the implanted tumor, and the location of the PEG within the brain as an indication of
where the novel nanoparticles end up. All of this information is potentially useful to
investigators interested in increasing the efficacy of nanoparticle related cancer therapies, and
specifically radiation therapy. In particular, understanding the precise localization of the
novel INPs is important because it can allow researchers to determine differences in
treatment success based on nanoparticle localization. For example, it could allow researchers
to discern differences in treatments utilizing INPs that localize in the membrane, cytosol, or
the nucleus, and what phenomena allow for specific localization.
From the 10X images it is clear the PEGylated nanoparticles accumulate in the tumor
region. This is a well-documented phenomenon called the enhanced permeability and
retention (EPR) effect [13] of nanoparticles and other molecules and it is caused by the
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presence of incomplete basal membranes and gaps in endothelial cells frequently present in
tumor vasculature [19, 20]. Thus, regardless of the size of the PEG ligands on the INP, there
is a strong propensity for nanoparticles to accumulate in the tumor interstitium, given they
have enough time to circulate in the blood and eventually deposit there. Additionally, Figure
6 supports the notion that once in the interstitium, the PEGylated INPs can translocate
through diffusion or convection to noncancerous regions within the invasive tumor [19]. This
is an especially important revelation in regards to determining the final efficacy of radiation
therapy, because it demonstrates there is potential for the radiation dose enhancement of
heavy atom based nanoparticles to also effect noncancerous tissue within a tumor.
One of the major pieces of evidence this research supports is the localization of the
PEGylated nanoparticles on the exterior of groups of cells and in the voids between cells
where tight junctions are not present. Additionally, the absence of the PEG signals within the
cells, specifically in regions also expressing tdTomato, should be noted. This supports the
conclusion that these INPs do not penetrate the cell in detectable quantities within 24 hours
of the last INP injection. There are several possible explanations for this effect, with many
relating to the PEG ligands on each INP. In order to increase the circulation time of the
nanoparticles, PEG is attached because it is relatively hydrophilic for a hydrocarbon polymer,
due to its polar ether linkages, allowing it to remain in the blood for longer periods. In
addition, PEG often acts to mask the nanoparticles from non-specific cellular uptake by
decreasing protein adsorption to the nanoparticle underneath, leading to an increase in
specific cellular uptake if conjugated biomolecules are present and an increase in the amount
of nanoparticles that eventually deposit in the interstitium of a tumor [14, 16, 17, 19]. PEG
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also increases the hydrodynamic radius of the nanoparticle inhibiting renal excretion and
allowing a further increase in circulation time.
Nonetheless, though the ligation of PEG to the INPs has the effect of potentially
increasing the number of nanoparticles that may deposit in the tumor, it may also limit the
amount that enters the cells via phagocytosis or pinocytosis. This is because the PEG coating
inhibits protein adsorption and thus receptor-mediated endocytosis. Thus, PEGylated
nanoparticles may become trapped in the interstitium and not permitted readily into the cells.
Additionally, there is some evidence that if the INP is slightly ionic in character, the
amphiphilic nature of the PEGylated INP may allow it to remain within cell membranes and
resist passing into the cytosol [16].
The localization of the INPs in the vasculature of the brain both within and outside of the
tumor region is supported in the images presented, especially in Figure 2 and Figure 3.
Though, the PEG signal is detectable when far from the tumor site, it is not nearly as
widespread and does not exist as much outside of the vasculature as within the tumor region.
Nonetheless, substantial deposition must occur in the vasculature as Figure 3 supports,
showing more complete vessels than the endothelial marker CD31 staining is capable of.
This is evident because in the same region CD31 and PEG staining overlap, however PEG
staining continues to mark the blood vessels while CD31 ceases to completely do so. This
could be because more PEG molecules are present in these vessels at the surface exposed to
the incubation fluid, where as CD31 is a protein used for intracellular junctions and thus may
be secluded from the surface in many locations. Likewise, within the tumor region there is
some evidence that supports the hypothesis that the INPs are localizing in the vasculature,
however the CD31 staining is rather diffuse and many clear vessels are not always easy to
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identify. Additionally, the vast presence of PEG signal in the tumor may mask some of the
specificity of the accumulation within the tumor vasculature. It should also be noted that
when the cells are implanted an injury is created leading to a small amount of bleeding. If
this injury does not fully heal by the time the INP is injected, then there is a chance the injury
can contribute to the wide distribution of INP within and around the tumor site.
Additionally, it is worth discussing the ordinary size of glioblastomas found in human
brains and the proportional size presented in this study. In humans, glioblastoma tumors are
most often found occupying a total of about 2 percent of the brain’s entire volume. This is
rather large and when projected into a mouse model corresponds to roughly 9 microliters of
tumor volume out a total brain volume of 450 microliters. In this study, the cross section
presented in the tile-scan image shows a tumor with an approximate average radius of 1.37
mm. If the tumor is assumed to be spherical in shape then the total volume of the tumor is
roughly 10.8 microliters. This is slightly larger than the average but not by a great deal and
thus the tumor could likely be expected to behave in a similar manner in regards to INP
uptake. Also it should be noted that the U-1242MG cell line is a very invasive tumor and
potential satellite tumors are possible in regions of the brain separated from the main tumor
mass. If this occurs, the physical and chemical structure of the tumor microenvironments
may be altered in more than one region of the brain leading to a potential increase in the
overall INP retention. This is important because there could be regions of the imaged section
affected by tumor cells not in the plane of the imaged section but in the same
microenvironment.
Though this imaging study showed some clear results and evidence in support of where
the novel INPs localize in murine brains implanted with U-1242MG tumors, there might
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need to be more work performed in order to rule out several alternative explanations for the
results obtained. First, in order to confirm or deny the conclusion that the INPs localize
solely outside of the cells and do not penetrate the cell membrane, a staining protocol in
which the cell membranes are made permeable to allow for intracellular immunostaining to
be performed could be done. This could be done with permeabilizing molecules like saponin,
Triton X-100, or Tween 20, that make either reversible or permanent holes in the cell
membranes allowing both primary and secondary antibodies to diffuse through the cell
membrane and attach to intracellular antigens, possibly including intracellular PEG [24].
Another factor that may obscure the results is that the endothelial marker protein CD31
(also known as PECAM1) used in this imaging is also expressed on the surfaces of many
blood components including platelets and white blood cells, specifically monocytes,
neutrophils and some T cells, though these mice lack T cells [25]. If these cells were able to
exit the tumor via the leaky vasculature and remain in the interstitium, there could be nonspecific staining occurring. If so, then within the tumor region it may be harder to detect
blood vessels present and thus staining protocols with antibodies specific for platelet or white
blood cell surface proteins could be used to confirm or deny their presence within a tumor, or
a more specific endothelial cell marker could be selected such as CD34, CD54, CD45,
VEGF-R2, vWF, Tek, or several others [26].
Lastly, the duration between when the mice received their INP injections and when the
tissue was harvested could have a significant impact in the total uptake of the deposited INPs.
In order to determine the uptake over time of the INP into the tumor cells, an experiment
assessing the differences in cellular uptake of the INPs versus duration between injection and
tissue harvesting could be performed.
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VI.

Conclusion:
Ultimately, through the use of both low-power and high-power conventional and confocal

fluorescence light microscopy techniques, substantial preliminary evidence in the localization
of novel Iodine-based nanoparticles within murine brains containing implanted human
glioma U-1242MG tumors was obtained. This was done through the probing of the
endothelial cell marker CD31, the tumor-expressed fluorescent protein tdTomato, and the
INP conjugated poly(ethylene glycol), and their respective immunocytochemistry primary
and secondary antibodies. Among such evidence was that the novel INPs from Nanoprobes
Inc. localized primarily in and around the tumor region nearly uniformly throughout
cancerous and noncancerous cells. Additionally, the INPs localized primarily in the brain’s
vasculature when found outside of the tumor region. There is also evidence that the INPs did
not enter the cells in significant quantities but rather remained in the interstitium and along
the exterior of cell clusters. In the end, though there are some additional procedures that can
be performed to further confirm the results obtained, this evidence may still support further
research into how these nanoparticles may be used in the treatment of cancer through
radiation dose enhancement. Additional treatment methods including drug delivery,
photothermal dose enhancement, and future nanoparticle based therapies and technologies
may also benefit from this study.
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